Trevi Therapeutics (TRVI) analyst forecast and price target
Analyst forecast
Consensus of 12 analyst ratings
Based on 6 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Jones Trading | Maintained | Buy | $28.00 from $24.00 | Aug 14, 2026 |
| Oppenheimer | Maintained | Outperform | $25.00 from $24.00 | Aug 7, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $30.00 from $25.00 | Aug 7, 2026 |
| BMO Capital | Initiated Coverage | Outperform | $36.00 | Jul 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $24.00 from $21.00 | Jul 20, 2026 |
| B. Riley Securities | Maintained | Buy | $31.00 from $21.00 | Jul 20, 2026 |
| Needham | Maintained | Buy | $23.00 | May 20, 2026 |
| Needham | Maintained | Buy | $23.00 from $24.00 | May 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | May 6, 2026 |
| D. Boral Capital | Maintained | Buy | $19.00 | Apr 17, 2026 |
| Jones Trading | Maintained | Buy | $24.00 from $25.00 | Mar 19, 2026 |
| Needham | Maintained | Buy | $24.00 from $22.00 | Mar 18, 2026 |
| D. Boral Capital | Maintained | Buy | $19.00 | Mar 18, 2026 |
| Morgan Stanley | Maintained | Overweight | $18.00 from $19.00 | Mar 18, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | Mar 9, 2026 |
| D. Boral Capital | Maintained | Buy | $19.00 | Mar 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | Jan 9, 2026 |
| D. Boral Capital | Maintained | Buy | $19.00 | Jan 8, 2026 |
| Stifel | Maintained | Buy | $18.00 from $15.00 | Dec 19, 2025 |
| Leerink Partners | Maintained | Outperform | $16.00 from $13.00 | Nov 20, 2025 |
Frequently asked questions
What is the price target for TRVI stock?
The average 12-month analyst price target for Trevi Therapeutics (TRVI) is $29.00, with a high estimate of $36.00 and a low of $24.00, across 6 analysts.
Is TRVI a buy, sell, or hold?
Analysts covering Trevi Therapeutics currently average a Buy rating: 12 buy, 0 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for TRVI?
The average price target of $29.00 implies 77.48% upside from the last price of $16.34.
What is the latest analyst rating on TRVI?
On Aug 14, 2026, Jones Trading maintained Trevi Therapeutics at Buy with a price target of $28.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.